AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03110458
Drug: SENS-111 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SENS-111 100mg is presented as 1 Oral Dispersible Tablet of SENS-111 100mg + 1 Oral Dispersible Tablet of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 500 mg for the entire study.
Trial: NCT00723307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White coated tablet; one tablet twice daily; 1.5 years duration
Trial: NCT03110458
Drug: SENS-111 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SENS-111 200mg is presented as 2 Oral Dispersible Tablet of SENS-111 100mg given twice on Day 1,second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 1000 mg for the entire study.
Trial: NCT03110458
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is presented as 2 Oral Dispersible Tablets of placebo given twice on Day 1, second intake given approximately 12 hours (9 to 15 hours) after the first intake and thereafter given once daily on Days 2 to 5 inclusive. The corresponding total dose will be 0 mg for the entire study.
Trial: NCT01131078
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
Trial: NCT00711126
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mcg IV
Trial: NCT00711126
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mcg oral
Trial: NCT02040298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily
Trial: NCT03002805
Drug: CBT-1®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed.
Trial: NCT02451917
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
Trial: NCT02300363
Drug: Treatment A (rosuvastatin)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin administered on Day 1 and Day 13
Trial: NCT02300363
Drug: Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
Trial: NCT00228358
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01724866
Drug: SPI-2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-2012 SC injection.
Trial: NCT01724866
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide given based on standard dose for chemotherapy.
Trial: NCT05688761
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term use of medications, particularly proton pump inhibitors
Trial: NCT03812003
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
Trial: NCT00111722
Drug: Comparator: placebo / Duration of Treatment - 1 day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02623868
Drug: CKD-519 50mg 2Tabs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after taking Standard meal, CKD-519 50mg 2Tabs. administration.
Trial: NCT02623868
Drug: CKD-519 100mg 1Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after taking Standard meal, CKD-519 100mg 1Tab. administration.
Trial: NCT02623868
Drug: CKD-519 100mg 1Cap.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after taking Standard meal, CKD-519 100mg 1Cap. administration.
Trial: NCT01456936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dummy placebo for each treatment arm
Trial: NCT01173601
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01173601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01773486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching hesperidin
Trial: NCT04737278
Drug: Cunermuspir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper Niacin Chelate, 6.06 mg per capsule Non-medicinal ingredients:~Organic evaporated cane juice powder, hypromellose, titanium dioxide
Trial: NCT00217425
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion per institutional guidelines.
Trial: NCT00217425
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
Trial: NCT03951077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule administered orally
Trial: NCT01473732
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
Trial: NCT02748785
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be continued
Trial: NCT01221662
Drug: Siwu Tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Siwu Tang 3 g bid(oral) continuously two weeks
Trial: NCT00854685
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0mg/kg s.c. - weekly
Trial: NCT00854685
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0mg/kg s.c. - fortnightly
Trial: NCT05590650
Drug: SZKJT(San-Zhong-Kui-Jian-Tang)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
Trial: NCT00854685
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg s.c. - weekly
Trial: NCT00854685
Drug: ART621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5mg/kg s.c. - fortnightly
Trial: NCT00854685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. - weekly
Trial: NCT00854685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. - fortnightly
Trial: NCT01080807
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Trial: NCT02222558
Drug: TSX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSX-002 are capsules with testosterone as the active ingredient.
Trial: NCT02987751
Drug: Glargine + Glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
Trial: NCT00896298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT02836652
Drug: acetylsalicylic acid (ASA) therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (81mg/day)
Trial: NCT00481702
Drug: MK0826, /Duration of Treatment : 8 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05757648
Drug: Non-buffered Anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-buffered LA, 2% lidocaine with epinephrine 1:100,000
Trial: NCT05757648
Drug: Buffered Anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cartridge of 2% lidocaine with epinephrine 1:100,000 alkalinized at 9:1 ratio with a resulting pH of 7.21 using 8.4% sodium bicarbonate solution per manufacturer.
Trial: NCT02248805
Drug: MGD007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
Trial: NCT02071199
Drug: 1X ACCS (Amnion-derived Cellular Cytokine Solution)
RxNorm normalized name: liver derivative complex Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
Trial: NCT02071199
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
Trial: NCT02071199
Drug: 0.3X ACCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
Trial: NCT03708718
Drug: Prednisolone 5 mg
RxNorm normalized name: prednisolone 5 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg prednisolone, once a day for 6 months
Trial: NCT03708718
Drug: Placebo oral capsule; From August 2020 'no additional treatment'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication
Trial: NCT03741972
Drug: iSGTL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
Trial: NCT01648634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is\>60kg)
Trial: NCT04353830
Drug: IBI939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Several dose levels will be evaluated for IBI939 administered as a single agent and in combination with Sintilimab. IBI939 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI939 may receive combination treatment with Sintilimab or IBI939+ Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
Trial: NCT01581736
Drug: U100 Humulin
RxNorm normalized name: Humulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
Trial: NCT02246816
Drug: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
Trial: NCT05888675
Drug: Weifuchun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group#Weifuchun group#was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and Ticeo monotherapy regimen.
Trial: NCT01948999
Drug: Anesthesia
RxNorm normalized name: anesthesia tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary induced state of analgesia
Trial: NCT03280017
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline infusion
Trial: NCT01250366
Drug: Placebo matching with INX-08189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, Once daily, 7 days
Trial: NCT00617604
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and subcutaneous injection
Trial: NCT01434134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, target dose 100 mg once daily
Trial: NCT01434134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 32 mg once daily
Trial: NCT00876161
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
Trial: NCT00876161
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00182039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
Trial: NCT02719496
Drug: IBEROGAST
RxNorm normalized name: Iberogast Softgels
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00808093
Drug: GSK256073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 100 mg study drug
Trial: NCT00867165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
Trial: NCT03694717
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
Trial: NCT01729299
Drug: acyl ghrelin
RxNorm normalized name: gellan gum (low acyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01479868
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
Trial: NCT05441631
Drug: Subcutaneous Insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine
Trial: NCT04317040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given on Day 1.
Trial: NCT00004092
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00004092
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00617604
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
Trial: NCT05261971
Drug: Etodolac 400 MG
RxNorm normalized name: etodolac 400 MG
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
Trial: NCT01102803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill
Trial: NCT00286351
Drug: Combined treatment with Arimidex and Zoladex before IVF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally or via NG tube once daily
Trial: NCT02778958
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
Trial: NCT00176813
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02387099
Drug: Standard Care after 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
Trial: NCT01011673
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac 30mg IVSS
Trial: NCT00700596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control or Placebo SA (30 % ethanolic solution)
Trial: NCT01632020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
Trial: NCT02098330
Drug: Ginkgo biloba & Methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
Trial: NCT02249351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01017666
Drug: BIIB014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
Trial: NCT01017666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
Trial: NCT00867230
Drug: FTS
RxNorm normalized name: tuftsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
Trial: NCT03760835
Drug: Dual release hydrocortisone (plenadren)
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of congenital adrenal hyperplasia
Trial: NCT01078441
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01078441
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00139230
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01847963
Drug: Sindhuvallathy mezhugu ( SVM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
Trial: NCT01847963
Drug: Kalladaippu Kudineer (KK) -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
Trial: NCT02714569
Drug: LY3202328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02714569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02714569
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01887132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03390465
Drug: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Trial: NCT01655927
Drug: Placebo: Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03427125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Drug